Brief: Eisai Completes Rolling BLA Submission For Subcutaneous Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) In The Us
31/10/2024 23:31
Oct 31 (Reuters) - BioArctic AB BIOAb.ST :
* EISAI COMPLETES ROLLING BLA SUBMISSION FOR SUBCUTANEOUS
MAINTENANCE DOSING OF LEQEMBI® (LECANEMAB-IRMB) IN THE US
Source text: ID:nWkr7XPYCd
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln